Prevention of cardiovascular events and safety of SGLT2 inhibitors compared to DPP-4 inhibitors in a real-world setting in patients with type 2 diabetes

Randomized controlled trials have shown that a new class of oral antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors, reduces the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, the risk of cardiovascular events and the safety associated with their use in the real-world setting remain uncertain. This state of practice:

1. describes and compares the characteristics of new users;
2. compares the risk of cardiovascular events associated with SGLT2 inhibitors compared to DPP-4 inhibitors; and
3. compares the safety of SGLT2 inhibitors compared to DPP-4 inhibitors.